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Abstract
Objectives The evaluation of the pharmacological profile of the dried 50%
hydroalcoholic extract (50%HA) of Astragali radix in two different animal
models of articular damage resembling osteoarthritis and rheumatoid arthritis.
Methods Sodium monoiodoacetate (MIA) or complete Freund’s adjuvant (CFA)
was intra-articular injected (day 0) in the rat tibiotarsal joint to induce damages
mimicking osteoarthritis or rheumatoid arthritis. Pain measurements (responses
to non-noxious and noxious stimuli, spontaneous pain, articular pain) were
assessed on days 7 and 14. On day 14, the tibiotarsal joints were explanted in
order to measure the diameter and to assess histological evaluations. Further-
more, the plasmatic concentrations of inflammatory and anti-inflammatory
cytokines were measured.
Key findings A single administration of 50%HA (300 mg/kg per os) signifi-
cantly reduced both MIA-induced pain and CFA-induced pain (78% and 96%
pain relief, respectively). The repeated administration prevented the develop-
ment of hypersensitivity on day 14. The haematoxylin/eosin staining revealed
that 50% HA attenuated joint alterations in MIA-injected rats, and further-
more, the joint inflammatory infiltrate was reduced in both models (by about
50%). In CFA-treated rats, 50%HA lowered the plasmatic levels of the pro-
inflammatory cytokines interleukin-1b and tumour necrosis factor-a as well as
the joint diameter.
Conclusions The 50% hydroalcoholic extract of Astragali radix is a valuable can-
didate for the adjuvant treatment of articular diseases.
Introduction
Osteoarthritis (OA) and rheumatoid arthritis (RA) are the
major causes of joint disease among the ageing popula-
tion.[1,2] However, while OA mostly affects elderly people,
disabling approximately 30% of persons age ≥65 years, RA
is frequent between 30 and 50 years.[3,4]
In the articular cartilage of OA patients, the physical
damage is subsequently modulated by immunological,
genetic or cellular factors. The OA synovial membrane is
characterized by inflammatory component even if less pro-
nounced than in RA.[2,5] On the other hand, RA, whose
aetiology is still unknown, is a chronically inflammatory,
destructive joint disease, continuously sustained by a
plethora of activated cell types (dendritic cells and endothe-
lial cells, osteoclasts, T cells and B cells, monocytes/macro-
phages and synovial fibroblasts) in the synovial
membrane.[6–8] Furthermore, chronic pain is a hallmark of
both these categories of articular diseases, with nociceptive,
non-nociceptive and neuropathic features.[9–11]
Pharmacological care is quite different between these
arthritic diseases. While OA is mostly counteracted by
pain relieving agents, RA is managed by immune-
suppressive and anti-inflammatory therapy. Following the
NICE Guidelines for the osteoarthritis therapy, topical
non-steroidal anti-inflammatory drugs (NSAIDs) and
paracetamol should be considered onwards oral opioids,
cyclooxygenase 2 (COX-2) inhibitors or NSAIDs.
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Otherwise, when topical NSAIDs and paracetamol are not
sufficient for relieving pain of OA patients, the supple-
ment of opioids should be taken into account. Moreover,
intra-articular corticosteroid injections should be added
to core treatments for the relief of moderate-to-severe
pain.[12] Regarding to RA, the European League Against
Rheumatism (EULAR) recommends the use of the so-
called DMARDs (disease-modifying antirheumatic drugs)
as soon as pathology is diagnosed. Methotrexate and/or
glucocorticoids are considered the first-line agents.
Leflunomide or sulfasalazine can also be used. By con-
trast, non-responsive patients can be treated with biologi-
cal drugs in addition to conventional DMARDs, such as
the TNF-a inhibitors (infliximab, certolizumab pegol,
etanercept, golimumab and adalimumab), the IL-6 recep-
tor blocking monoclonal antibody, the tocilizumab, as
well as the IL-1 inhibitor, anakinra.[13]
However, since the chronicity of therapy and adverse
effects associated with the majority of these drugs, the man-
agement of arthritic diseases remains clinically challenging.
In this context, plant extracts with a favourable safety
profile emerge as interesting therapeutic resources for the
treatment of chronic pathologies.
In this context, Astragali radix from Astragalus mem-
branaceus (Fisc.) Bunge (Fabaceae) is one of the mostly
used medicinal herbs of the traditional Chinese medicine
having numerous medicinal properties and significant
safety profile. The herbal drug is recently introduced in the
European Pharmacopoeia.[14,15] Astragali radix extracts
have been reported to have several biological functions
among which immunomodulatory and hepatoprotective
ones.[16,17] Furthermore, antiviral and antioxidant activity
have been highlighted.[18,19] To note, the major active com-
pounds of Astragalus are flavonoids, saponins and polysac-
charides, reported to have anti-inflammatory effects[20,21]
and anti-arthritic activity.[22–24] Recently, we have chemi-
cally characterized and tested the antineuropathic effects of
different aqueous and hydroethanolic extracts from
Astragali radix. The most active extract of both in vitro and
in vivo experiments resulted a 50% hydroalcoholic extract
(50%HA).[25,26]
The aim of this study was to assess, for the first time,
the pharmacological profile of the Astragali radix phyto-
complex, as present in 50%HA, in two rat models of
articular diseases resembling OA and RA, respectively.
50% HA (300 mg/kg) was acutely and chronically admin-
istered in monoiodoacetate (MIA)-treated rats or com-
plete Freund’s adjuvant (CFA)-treated rats and pain
behavioural measurements were assessed. Moreover, ex-
vivo analyses were performed to evaluate joint alterations
and plasma levels of characteristic cytokines. The possible
application of the rapid clinically translatable botanical
50%HA was enquired.
Materials and Methods
Plant material, and analysis
The 50% hydroalcoholic dried extract of Astragali radix
(AxtragylTM) was purchased from Giellepi S.p.A. Health
Science Division. The extract was reported to contain 30%
maltodextrins as excipients. For the quantitative HPLC
analysis, the following standards were used: astragaloside
IV, European Pharmacopoeia (EP) reference standard
(97.8%) and formononetin (≥99% by HPLC) from
(Sigma-Aldrich, Milano, Italy). Dextrans with increasing
and defined molecular weights (5000, 150 000, 270 000,
670 000 Da) were from Sigma-Aldrich. The full characteri-
zation of the Astragalus extract was previously published[25]
and described in the supplementary material (Appendix
S1). An authentic sample of the commercial dried extract is
deposited at the Department of Chemistry, University of
Florence.
Animals
Male Sprague-Dawley (SD) rats (Envigo, Varese, Italy)
weighing approximately 200–250 g at the beginning of the
experimental procedure were used. Animals were housed in
CeSAL (Centro Stabulazione Animali da Laboratorio,
University of Florence) and used at least 1 week after their
arrival. Four rats were housed per cage (size 26 9 41 cm)
kept at 23  1 °C with a 12-h light/dark cycle, light at
7 a.m., and were fed a standard laboratory diet and tap
water ad libitum. All animal manipulations were carried
out according to the Directive 2010/63/EU of the European
Parliament and of the European Union Council (22
September 2010) on the protection of animals used for sci-
entific purposes. The ethical policy of the University of
Florence complies with the Guide for the Care and Use of
Laboratory Animals of the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996; University of
Florence assurance number: A5278-01). Formal approval to
conduct the experiments described was obtained from the
Animal Subjects Review Board of the University of Flor-
ence. Experiments involving animals have been reported
according to the ARRIVE guidelines.[27] All efforts were
made to minimize animal suffering and to reduce the
number of animals used.
Monoiodoacetate-induced osteoarthritis
Unilateral osteoarthritis was induced by injection of
monoiodoacetate (MIA; Sigma-Aldrich, Milan, Italy) into
the tibiotarsal joint.[10] On day 0, rats were slightly anaes-
thetized by 2% isoflurane, the left leg skin was sterilized
with 75% ethyl alcohol and the lateral malleolus located by
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palpation; then, a 28-gauge needle was inserted vertically to
penetrate the skin and turned distally for insertion into the
articular cavity at the gap between the tibiofibular and tar-
sal bone until a distinct loss of resistance was felt. Two mil-
ligrams of MIA in 25 ll saline was delivered into the left




Articular damage was induced by injection of complete Fre-
und’s adjuvant (CFA; Sigma-Aldrich, Milan, Italy) into the
tibiotarsal joint.[10,28] Briefly, the rats were lightly anaes-
thetized by 2% isoflurane, the left leg skin was sterilized with
75% ethyl alcohol and the lateral malleolus located by palpa-
tion; then, a 28-gauge needle was inserted vertically to pene-
trate the skin and turned distally for insertion into the
articular cavity at the gap between the tibiofibular and tarsal
bone until a distinct loss of resistance was felt. A volume of
50 ll of CFA was then injected (day 0). Control rats received
50 ll of saline solution (day 0) in the tibiotarsal joint.
Drug treatment
For the acute treatment, 50% HA was suspended in 1%
carboxymethylcellulose (CMC) and once administered
p.o. at the dose of 300 mg/kg on day 7 or on day 14 after
MIA or CFA injection. For the chronic treatment, 50% HA
(300 mg/kg p.o.) was administered every day for 2 weeks
starting from the 1st day of MIA or CFA injection.
Paw pressure test
The nociceptive threshold in the rat was determined with
an analgesimeter (Ugo Basile, Varese, Italy), according to
the method described by Leighton et al.[29] Briefly, a con-
stantly increasing pressure was applied to a small area of
the dorsal surface of the hind paw using a blunt conical
mechanical probe. Mechanical pressure was increased until
vocalization or a withdrawal reflex occurred while rats were
lightly restrained. Vocalization or withdrawal reflex thresh-
olds were expressed in grams. Rats scoring below 40 g or
over 75 g during the test before drug administration (25%)
were rejected. An arbitrary cut-off value of 100 g was
adopted. The data were collected by an observer who was
blinded to the protocol.
Incapacitance test
Weight bearing changes were measured using an incapaci-
tance apparatus (Linton Instrumentation, Palgrave, UK)
detecting changes in postural equilibrium after a hindlimb
injury.[30] Rats were trained to stand on their hind paws in
a box with an inclined plane (65° from horizontal). This
box was placed above the incapacitance apparatus. This
allowed us to independently measure the weight that the
animal applied on each hindlimb. The value considered for
each animal was the mean of five consecutive measure-
ments. In the absence of hindlimb injury, rats applied an
equal weight on both hindlimbs, indicating a postural equi-
librium, whereas an unequal distribution of the weight on
hindlimbs indicated a monolateral decreased pain thresh-
old. Data are expressed as the difference between the weight
applied on the limb contralateral to the injury and the
weight applied on the ipsilateral one (DWeight).
von Frey test
The animals were placed in 20 9 20 cm plexiglas boxes
equipped with a metallic meshy floor, 20 cm above the
bench. A habituation of 15 min was allowed before the test.
An electronic von Frey hair unit (Ugo Basile) was used: the
withdrawal threshold was evaluated by applying force rang-
ing from 0 to 50 g with a 0.2-g accuracy. Punctuate stimulus
was delivered to the mid-plantar area of each anterior paw
from below the meshy floor through a plastic tip, and the
withdrawal threshold was automatically displayed on the
screen. Paw sensitivity threshold was defined as the mini-
mum pressure required to elicit a robust and immediate
withdrawal reflex of the paw. Voluntary movements associ-
ated with locomotion were not taken as a withdrawal
response. Stimuli were applied on each anterior paw with an
interval of 5 s. The measure was repeated 5 times, and the
final value was obtained by averaging the five measures.[31]
Pressure application measurement test
The pressure application measurement (PAM from Ugo
Basile) was used to measure mechanical pain threshold of
the knee joint. A force transducer (2 mm diameter) is
mounted on the operator’s thumb, and a progressive quan-
tified force was applied for direct stimulation of the joint.
The rate of application of the force is decided by the opera-
tor. The force (gram-force; gf) which elicits the animal
response (normally, limb withdrawal) was recorded. The
value considered for each joint was the mean of five consec-
utive measurements. Data are expressed as the difference
between the force tolerated on the knee joint contralateral
to the injury and the force tolerated on the ipsilateral one
(D Force).
Histological evaluations
Animals were killed by cervical dislocation. Legs were cut
under the knee, flayed and fixed in 4% formaldehyde in
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phosphate-buffered saline (PBS) for 48 h at room tempera-
ture. Subsequently, samples were decalcified by 0.76 M
sodium formate and 1.6 M formic acid solution in H2O for
4 weeks with a change of solution every 7 days. At the end
of the decalcification, these samples were routinely dehy-
drated in alcohol and embedded in paraffin. Sections 6 lM
thick of tibiotarsal joint and of phlogistic-fibrous pannus
located around the join were obtained. Sections were
haematoxylin–eosin stained. In the phlogistic-fibrous pan-
nus sections, the number of inflammatory cells was
counted, and results were expressed as number of inflam-
matory cells/microscopic field. Sections of the joint were
analysed qualitatively by two independent observers in a
blind fashion.
Cytokine plasma levels
Plasmatic IL-1b, TNF-a, TGF-b1, IL-10 levels were evalu-
ated by ELISA method (eBioscience, San Diego, CA, USA),
using a specific anti-rat polyclonal antibody. To obtain
detectable levels of cytokines, plasma samples were lyophi-
lized and reconstituted in 1/5 of the initial volume. Range
sensitivity was 8–1000 pg/ml.
Joint diameter evaluation
Animals were killed, and legs ipsilateral to CFA injection
were cut and fixed as described before in ‘Histological eval-
uations’ section. Then, the diameter of the tibiotarsal joint
was measured using a digital caliper (150 mm).
Statistical analysis
Each value represents the mean  SEM of five rats per
group, performed in two different experimental sets.
Groups were as shown in the figures, and different groups
were used for acute and repeated treatments. The analysis
of variance was performed by ANOVA. A Bonferroni’s sig-
nificant difference procedure was used as post hoc compar-
ison. P values of less than 0.05, 0.01 or 0.001 were




According to a previous characterization,[25] the drug
extract ratio (DER) of 50%HA was 1/4–6. Characteristic
constituents, namely saponins (expressed as astragaloside
IV) and isoflavones (expressed as formononetin), were
analysed by LC/DAD/MS. The developed analytical meth-
ods were similar to those reported in the literature for the
simultaneous determination of isoflavones and saponins,
modified according to our specific needs. To achieve opti-
mized separation, the same gradient reported in the litera-
ture was used, with slight modifications. Astragaloside IV
and formononetin international standards were used to
quantify saponins and isoflavones, respectively. Calibration
curves of both constituents were prepared between 0.01
and 10 lg/ml, and each calibration level was analysed six
times by LC-DAD (isoflavones) or LC-MS (saponins)
methods. A good linear relationship over the tested ranges
was found. The LOQ of formononetin was 0.5 lg/ml and
the LOQ of astragaloside IV was 0.01 lg/ml. According to
the literature data, very low amounts of both classes of con-
stituents were found, as reported in Table S1.
According to the HPLC analysis, polysaccharides repre-
sent the major constituents of the extracts. Accordingly, the
extracts were firstly analysed by NMR to elucidate the
monomers present in the polysaccharide sequence and then
by dynamic light scattering (DLS) to give an averaged
molecular weight. The 1H NMR spectra of the Astragalus
extract displayed two clear peaks in the anomeric region
(between 4.0 and 5.4 ppm), and all three extracts were very
similar (Figure S1). The peaks between 4.00 and 5.30 ppm
were clearly identified as the anomeric protons. The other
carbinolic peaks overlap but can be easily observed in the
HMQC experiments (Figure S2) and assigned to hexose
moieties.
The molecular weight of the polysaccharides was evalu-
ated by DLS, namely a calibration curve was created using
commercial dextrans with increasing and defined molecu-
lar weights (Mw: 5000, 150 000, 270 000, 670 000). Con-
centrations of the extract in the tested solutions (0.5–
1 mg/ml dried extract) were optimized to have a good
calibration curve with an acceptable PDI and count rate.
The sample showed two populations of polysaccharides,
the main one ranging from 75% to 97%, and the molec-
ular weights of populations were calculated by the value
of Zaverage using the calibration curve of standard dextrans
(Table S2).
Behavioural measurements
Behavioural tests were assessed to evaluate the pain reliever
effect of single and repeated administrations of 50%HA on
MIA-treated rats or CFA-treated rats.
As shown by Paw pressure test, on day 14 from injection,
MIA significantly lowered the pain threshold on the ipsilat-
eral paw in response to a mechanical noxious stimulus (pret-
est, Figure 1a) as well as increased the hindlimb bearing
between the contralateral and the ipsilateral paw, as assessed
by the incapacitance test (pretest, Figure 1b). A single injec-
tion of 50%HA (300 mg/kg p.o.) on MIA plus vehicle group
was able to significantly reduce both the withdrawal
© 2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology, 69 (2017), pp. 1858–1870 1861
Mario Maresca et al. Preclinical effect of Astragalus against arthritis
threshold in response to a noxious mechanical stimulus and
postural unbalance, peaking 45 min after injection (Fig-
ure 1). However, the effect of MIA on pain perception was
visible also on day 7. As shown in Figure S3, MIA injection
reduced both the weight tolerated on the ipsilateral paw and
increased the postural unbalance (pretest, Figure S3a and
S3b). 50%HA (300 mg/kg), acutely injected p.o. on MIA
plus vehicle-treated animals, was able to significantly
increase the withdrawal threshold in response to a noxious
mechanical stimulus and to lower the D weight between the
contralateral and the ipsilateral paw, exerting the maximum
effect 30 min after injection (Figure S3a and S3b). The pain
reliever effect of 50%HA has been highlighted even after
daily administration. As depicted in Figure 2a, on day 14,
50%HA repeatedly administered (300 mg/kg p.o.), signifi-
cantly increased the weight tolerated on the ipsilateral paw
(47.5  1.7 g, MIA plus vehicle vs 65.0  3.5 g, MIA plus
50%HA) (Figure 2a). Furthermore, chronic 50%HA signifi-
cantly reduced spontaneous pain (48.1  9.2 g, MIA plus
vehicle vs 25.0  5.0 g, MIA plus 50%HA) (Figure 2b). As
measured by von Frey apparatus, MIA, 14 days after injec-
tion, lowered the pain threshold in response to a non-nox-
ious mechanical stimulus, meanwhile 50%HA, daily
administered, was not able to significantly prevent the pain
sensitivity increase (Figure 2c). Finally, as depicted in Fig-
ure 2d, the PAM test allowed to evaluate the articular pain
as the difference (D Force) between the force tolerated on
the joint contralateral to the injury and the force tolerated
on the ipsilateral one. On day 14, D force was increased in
MIA plus vehicle rats with respect to vehicle plus vehicle
group (284.0  38.9 gf, MIA plus vehicle vs 61.7  17.3 gf,
vehicle plus vehicle). 50%HA, daily injected, completely
reverted articular pain (41.5  14.6 gf) (Figure 2d).
As shown in Figure 3, CFA significantly decreased the
withdrawal threshold in response to a noxious mechani-
cal stimulus 14 days after injection (pretest, Figure 3a).
Moreover, postural unbalance was increased after CFA
injection (pretest, Figure 3b). Paw pressure test led us to
appreciate that a single administration of 50%HA
(300 mg/kg p.o.) was able to significantly increase the
weight tolerated on the ipsilateral paw up to 45 min after
injection (Figure 3a). Furthermore, the herbal extract
reduced CFA-induced spontaneous pain from 15 to
45 min, as shown by the incapacitance test (Figure 3b).
As depicted in Figure 4a, CFA significantly decreased the
withdrawal threshold in response to a noxious mechani-
cal stimulus as well as reduced spontaneous pain also on
day 7 after injection (Figure 4a and 4b). However, 50%
HA (300 mg/kg), daily administered per os, was able to
exert pain reliever activity on day 14, where it increased
the weight tolerated on the ipsilateral paw (38.0  3.3 g,
CFA plus vehicle vs 54.7  2.4 g, CFA plus 50%HA)
(Figure 4a). Moreover, as assessed by the incapacitance
test, chronic treatment of 50%HA significantly reduced
the postural unbalance (60.8  6.3 g, CFA plus vehicle
vs 28.4  5.4 g, CFA plus 50%HA) (Figure 4b). The von
Frey apparatus showed that 50%HA, daily administered,
reduced the withdrawal threshold lowering in response to
Figure 1 Monoiodoacetate-induced arthritis. 50%HA acute treatment, behavioural measurements. 50%HA (300 mg/kg) was administered p.o.
on day 14 after monoiodoacetate injection. Behavioural tests were performed 15, 30, 45, 60 and 75 min after astragalus administration. (a) The
response to a noxious mechanical stimulus was measured by the Paw pressure test. (b) Spontaneous pain was assessed measuring the hindlimb
weight bearing alterations using the incapacitance test; data are expressed as the difference between the weight applied on the limb contralateral
to the injury and the weight applied on the ipsilateral limb. Each value represents the mean  SEM of five rats per group, performed in two dif-
ferent experimental sets. ***P < 0.001 vs vehicle plus vehicle (pretest). ^P < 0.05, ^^P < 0.01 and ^^^P < 0.001 vs monoiodoacetate plus vehicle
(pretest).
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a mechanical non-noxious stimulus induced by CFA
(20.1  1.7 g, CFA plus vehicle vs 10.4  0.9 g, CFA
plus 50%HA) (Figure 4c). Furthermore, as depicted in
Figure 4d, articular pain dramatically increased after the
CFA injection (6.4  5.6 gf, vehicle plus vehicle vs
176  13.9 gf, CFA plus vehicle), meanwhile 50%HA
lowered the D force impairment tolerated on the con-
tralateral and ipsilateral joint (89.7  10.8 gf) (Fig-
ure 4d).
Seven days of treatment with 50%HA was not enough to
induce pain relief (24 h after administration) in both mod-
els (Figures 2a and 2b, and 4a and 4b).
Morphological evaluation of tibiotarsal joint
The effect of repeated administration of 50%HA on mor-
phological derangement of tibiotarsal joint was evaluated
14 days after MIA or CFA injection.
In MIA osteoarthritis model, the intra-articular injection of
MIA caused fibrin accumulation and broad degeneration of
the articular cartilage characterized by thickness reduction,
ulceration and scarring. As result, the intra-articular space
markedly decreased with respect to the normal joint. 50%HA
(300 mg/kg) daily administration weakly reduced the fibrin
accumulation (Figure 5, panel a). Moreover, the treatment
Figure 2 Monoiodoacetate-induced arthritis. 50%HA repeated treatment, behavioural measurements. After monoiodoacetate injection (day 0),
50%HA (300 mg/kg) was daily administered p.o. for 14 days. The Paw pressure test and the incapacitance test were performed on days 7 and
14, 24 h after the last treatment; the von Frey test and the PAM test were performed on day 14, 24 h after the last treatment. (a) The response
to a noxious mechanical stimulus was measured by the Paw pressure test. (b) Spontaneous pain was assessed measuring the hindlimb weight
bearing alterations by the incapacitance test; data are expressed as the difference between the weight applied on the contralateral and ipsilateral
limbs. (c) The response to a non-noxious mechanical stimulus was measured by the von Frey test. (d) Articular pain was assessed by the PAM test;
data are expressed as the difference between the forces tolerated on the contralateral and the ipsilateral joints. Each value represents the
mean  SEM of five rats per group, performed in two different experimental sets. *P < 0.05, **P < 0.01 and ***P < 0.001 vs vehicle plus vehicle.
^P < 0.05 and ^^P < 0.01 vs MIA plus vehicle.
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with Astragalus extract significantly lowered the number of
inflammatory cells in the phlogistic-fibrous tissue located
around the joint, as shown in Figure 5 (panels b and c).
As shown in Figure 6, CFA injection induced the total
ablation of the joint space that appears replaced by fibrous
tissue. Articular cartilage was completely disappeared (CFA
plus vehicle vs vehicle plus vehicle) (Figure 6, panel a).
Animals treated with the herbal extract showed morpholog-
ical features very similar to those expressed by animal trea-
ted with CFA: ablation of the joint space, which is occupied
by fibrous tissue. The treatment with 50%HA significantly
reduced the number of inflammatory cells in the phlogis-
tic-fibrous tissue located around the joint, as shown in Fig-
ure 6 (panels b and c). Moreover, CFA injection increased
the joint diameter with respect to the vehicle plus vehicle
group, as measured with caliber (9.16  0.44 mm, CFA
plus vehicle vs 6.03  0.03 mm, vehicle plus vehicle) (Fig-
ure S4a). On the other hand, chronic administration of
50%HA significantly reduced articular swelling
(7.83  0.16 mm) (Figure S4a).
Cytokine levels evaluation
On day 14 days after the CFA injection, the biochemical
analysis of plasma fluids was performed. The evaluation
revealed a twofold increase in Il-1b levels in CFA-treated
animals with respect to vehicle plus vehicle group. As
shown in Table 1, 50%HA chronic treatment was able to
completely prevent the Il-1b level increase (Table 1).
Moreover, the herbal extract significantly reduced the TNF-
a plasma concentration increase caused by CFA
(18.0  2.8 pg/ml, CFA plus 50%HA vs 35.0  3.4 pg/ml,
CFA plus vehicle). On the other hand, 50%HA did not
affect the plasma levels of TGF-b and IL-10. Notably, CFA
did not influence the concentration of TGF-b1 14 days
after injection (77.8  1.5 pg/ml, CFA plus vehicle vs
85.4  2.8 pg/ml, vehicle plus vehicle).
Discussion
The present data highlight the anti-arthritic effect of a 50%
hydroalcoholic extract obtained from Astragali radix (50%
HA) in two rat models of articular painful damages.
In the first paradigm, the intra-articular injection of MIA
provided a monolateral osteoarthritis with features, such as
cartilage fibrillation, formation of osteophytes, thickening
and loss of cartilage, similar to those seen in humans.[32–34]
Structural changes of the articular morphology are related to
the onset of a long-lasting inflammatory pain which acquires
neuropathic hallmarks starting from the 14th day after MIA
injection.[10,35] The present results showed that 50%HA
(300 mg/kg) is highly active after a single oral administra-
tion reducing the response to a suprathreshold stimulation
(hyperalgesia-related stimulation) and the postural unbal-
ance (spontaneous pain) both 7 and 14 days after MIA
injection. These data led us to appreciate that the 50%HA is
able to relieve pain sensitivity during both the inflammatory
and the, subsequent, neuropathic phase of osteoarticular
Figure 3 Complete Freund’s adjuvant-induced arthritis. 50%HA acute treatment, behavioural measurements. 50%HA (300 mg/kg) was adminis-
tered p.o. on day 14 after complete Freund’s adjuvant injection. Behavioural tests were performed 15, 30, 45, 60 and 75 min after astragalus
administration. (a) The response to a noxious mechanical stimulus was measured by the Paw pressure test. (b) Spontaneous pain was assessed
measuring the hindlimb weight bearing alterations using the incapacitance test; data are expressed as the difference between the weight applied
on the limb contralateral to the injury and the weight applied on the ipsilateral limb. Each value represents the mean  SEM of five rats per
group, performed in two different experimental sets. **P < 0.01 and ***P < 0.001 vs vehicle plus vehicle (pretest). ^P < 0.05, ^^P < 0.01 vs
complete Freund’s adjuvant plus vehicle (pretest).
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pain. Moreover, the repeated treatment with 50%HA for
14 days reduces spontaneous pain and completely reverts
both pain evoked by noxious stimulus applied on the paw as
well as pain directly measured on the joint. As such, the
effect of chronic 50%HA on pain relief is accompanied with
the morphological recovery of the joint. The histological
evaluation confirms that the daily administration of Astra-
galus extract reduces inflammatory infiltrate and fibrin accu-
mulation around the joint. Thus, the capability of 50%HA
to decrease the painful sensitivity could be due to a dual
action: by a mechanism that quickly lowers pain and inflam-
mation and favouring articular restoration.
50%HA relieves pain even in rats where arthritis was
induced by the adjuvant injection. CFA, once injected into
the tibiotarsal joint, causes an inflammatory arthritis
resembling to rheumatoid arthritis.[36] Inflammation
induced by CFA begins on the 3rd day after injection and
holds steady up to day 14, increasing pain sensitivity.[37,38]
Interestingly, Astragalus extract was able to completely
revert pain, after a single injection on day 14, when the dis-
ease was already full-blown. Moreover, 50%HA efficacy was
maintained also after repeated treatments reducing the pain
towards noxious and non-noxious mechanical stimuli as
well as spontaneous and articular pain. Histologically, CFA
Figure 4 Complete Freund’s adjuvant-induced arthritis. 50%HA repeated treatment, behavioural measurements. After complete Freund’s adju-
vant injection (day 0), 50%HA (300 mg/kg) was daily administered p.o. for 14 days. The Paw pressure test and the incapacitance test were per-
formed on days 7 and 14, 24 h after the last treatment; the von Frey test and the PAM test were performed on day 14, 24 h after the last
treatment. (a) The response to a noxious mechanical stimulus was measured by the Paw pressure test. (b) Spontaneous pain was assessed measur-
ing the hindlimb weight bearing alterations by the incapacitance test; data are expressed as the difference between the weight applied on the
contralateral and ipsilateral limbs. (c) The response to a non-noxious mechanical stimulus was measured by the von Frey test. (d) Articular pain
was assessed by the PAM test; data are expressed as the difference between the forces tolerated on the contralateral and the ipsilateral joints.
Each value represents the mean  SEM of five rats per group, performed in two different experimental sets. ***P < 0.001 vs vehicle plus vehicle.
^^^P < 0.001, ^^P < 0.01 vs complete Freund’s adjuvant plus vehicle.
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injection led to an intense inflammatory state and swelling
severely altering the joint morphology.[39] Although
chronic 50%HA does not enhance the morphological
recovery of the joint, the articular inflammation is reduced
as well as the joint diameter. The slowing of disease pro-
gression, as evidenced by histological data, was confirmed
analysing the levels of pro-inflammatory cytokines TNF-a
and Il-1b that are strongly involved in the pathogenesis of
RA.[40,41] 50%HA significantly lowered the plasmatic levels
of both TNF-a and Il-1b. Conversely, 50%HA did not
influence the concentrations of the anti-inflammatory
TGF-b1 and IL-10, both related to RA-induced inflamma-
tion.[42,43]
Several bioactive compounds were found in
Astragali radix, namely triterpene saponins mainly astraga-
loside IV,[44] flavonoids, mainly calycosin and
formononetin[45] and polysaccharides.[46] Chemical analy-
sis of the investigated 50% HA (DER, 1/4-6[25]) revealed
that it is mainly constituted of polysaccharides. Isoflavones
represent 0.13% and were identified as calycosin, both in
the free and in the glycosylated form, and formononetin.
Saponins content is threefold higher than flavonoids
(0.47%).[25] Previously published data on these compounds
sustain the present evidence of Astragalus efficacy in articu-
lar diseases. Huh and colleagues (2010) highlighted a con-
troversial activity of formononetin on human subchondral
osteoblasts obtained from healthy and osteoarthritic
patients. Although formononetin increased the osteolytic
activity in normal conditions, it interfered with the osteo-
blast metabolism limiting the subchondral remodelling
during disease.[23] Calycosin, intra-articular injected in an
animal model of OA, decreased the synovial fluid
Figure 5 Monoiodoacetate-induced arthritis. 50%HA repeated treatment, joint histological evaluation. 50%HA (300 mg/kg) was p.o. daily adminis-
tered for 14 days. Ex-vivo analysis was performed on day 14. The panel a shows haematoxylin and eosin staining of longitudinal section of tibiotarsal
joint of vehicle plus vehicle, monoiodoacetate plus vehicle, monoiodoacetate plus 50%HA-treated animals. In the panel b, phlogistic-fibrous pannus
located around the joint sections was stained with haematoxylin and eosin and the inflammatory infiltrate was shown. In the panel c, the quantitative
results of densitometry are given in the graph. Pictures are representative of histological preparations from five animals per group. Bars = 100 lm.
**P < 0.01 vs vehicle plus vehicle, ^P < 0.05 vs monoiodoacetate plus vehicle. [Color figure can be viewed at wileyonlinelibrary.com]
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production as well as reduced the subchondral bone dam-
age. Intriguingly, the anti-inflammatory activity exerted by
calycosin is not mediated by a cyclooxygenase (COX) inhi-
bition mechanism.[22] Moreover, astragaloside IV inhibited
macrophage activation during RA preventing the inflam-
matory-mediated cartilage and bone erosion,[24] and the
immunomodulatory activity of Astragalus saponins is well
known.[47,48] Finally, polysaccharides isolated from
Astragali radix lowered plasma levels of TNF-a and Il-1b
and reduced the inflammation of knee synovial tissue in a
rat model of RA.[49] Furthermore, articular disease is char-
acterized by oxidative stress, occurring both acutely, with
augmented local ROS production, and chronically, conse-
quently to the inflammatory response and tissue
Figure 6 Complete Freund’s adjuvant-induced arthritis. 50%HA repeated treatment, joint histological evaluation. 50%HA (300 mg/kg) was
p.o. daily administered for 14 days. Ex-vivo analysis were performed on day 14. The panel a shows haematoxylin and eosin staining of longi-
tudinal section of tibiotarsal joint of vehicle plus vehicle, complete Freund’s adjuvant plus vehicle, complete Freund’s adjuvant plus 50%HA-
treated animals. In the panel b, phlogistic-fibrous pannus located around the joint sections was stained with haematoxylin and eosin, and the
inflammatory infiltrate was shown. In the panel c, the quantitative results of densitometry are given in the graph. Pictures are representative
of histological preparations from five animals per group. Bars = 100 lm. **P < 0.01 vs vehicle plus vehicle, ^P < 0.05 vs complete Freund’s
adjuvant plus vehicle. [Color figure can be viewed at wileyonlinelibrary.com]
Table 1 Complete Freund’s adjuvant (CFA)-induced arthritis. 50%
HA (HA) repeated treatment, plasma cytokine levels
Protein concentration (pg/ml)
vehicle + vehicle CFA + vehicle CFA + 50%HA
IL-1b 18.4  2.0 42.7  1.1* 22.6  0.5**
TNF-a 10.0  2.5 35  3.4* 18  2.8**
TGF-b1 85.4  2.8 77.8  1.5 97.4  5.3
IL-10 2.9  0.9 20.6  3.5* 17.3  2.4
After CFA injection (day 0), 50%HA (300 mg/kg) was daily adminis-
tered p.o. for 14 days. On day 14, plasma samples were collected and
analysed by ELISA kit. Protein concentrations are expressed in pg/ml.
Each value represents the mean  SEM of five rats performed in two
different experimental sets. *P < 0.01 compared to vehicle plus vehi-
cle rats; **P < 0.05 vs CFA plus vehicle.
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degeneration at the joint level. Notably, oxidative levels
increase contributes to pain sensitization in arthritis.[10]
Interestingly, polysaccharides, flavonoids and saponins pos-
sess considerable activity against oxidative imbal-
ance,[46,50,51] and 50%HA has shown antioxidant and pain
relieving activity in a rat model of neuropathic pain.[26] In
this context, the antioxidant properties of bioactive com-
pounds present in 50%HA could explain at least in part the
pain relieving efficacy and the anti-inflammatory activity of
the herbal extract.
Taken together, the present results show the ability of
50%HA to block articular pain after acute and repeated
treatments. Pain relief and joint restoration induced by
50%HA may be related to the presence of chemical compo-
nents able to reduce the inflammatory state and limit the
bone remodelling of the joint, although differently between
the two kinds of arthritis. The marked decrease in pro-
inflammatory cytokines, such as TNF-a and Il-1b, obtained
after repeated administration of 50%HA is a significant
hallmark of chronic inflammation decrease.[38] To note,
formononetin and astragalosides have been proven as
antinociceptive compounds in inflammatory pain.[52,53]
50%HA is a candidate to be a widespread pain killer
active against different kinds of persistent pain as neuro-
pathic[26] and arthritic conditions [present data]. Efficacy is
supported by a good safety profile highlighted by monitor-
ing neurological, hepatic and renal alterations.[26]
Conclusions
This study provides evidences of the pain reliever efficacy
of the Astragali radix 50% hydroalcoholic extract. Preclini-
cal conditions mimicking both osteoarthritis and rheuma-
toid arthritis are sensitive to 50%HA after acute and
repeated oral treatments. The possibility to directly modify
joint inflammation and derangement candidates 50% HA
as adjuvant for the prevention and the treatment of arthritis
induced by different pathogenesis. Safety characteristics
and the possible use as dietary supplement make 50%HA
suitable for a clinical validation.
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